Site icon pharmaceutical daily

Hikma joins $853M US market with its generic major depressive disorder tablets

hikma pharmaceuticals

hikma pharmaceuticals

Hikma Pharmaceuticals said on Friday that its US subsidiary West-Ward Pharmaceuticals Corp. has launched two doses of generic Pfizer’s Pristiq (Desvenlafaxine Succinate) ER Tablets.

West-Ward’s Desvenlafaxine Succinate ER Tablets, with doses of 50 mg and 100 mg, are made for the treatment of major depressive disorder, and are in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs).

Hikma says that, according to IMS Health, US sales of Desvenlafaxine Succinate ER Tablets in 50 mg and 100 mg strengths were approximately $853 million in the 12 months ending January 2017.

Exit mobile version